Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

RTGN
Sort by: Date|Relevance

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic ey...
Streetwise Reports | December 3, 2019 |

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. Early this morning, gene therapy focused biopharmaceutical company IVERIC bio Inc. (I...
Streetwise Reports | October 29, 2019 |

DIAGNOS poised for parabolic move as first of new cardio AI Applications comes to market

DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company that pioneered ' C omputer A ssisted R etinal A nalysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients a...
James O'Rourke | May 5, 2020 |

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. In a March 4 BTIG research note, analyst Thomas Shrader reported that Biogen Inc. (BIIB:NASDAQ) entered into an agreement to acquire Nightstar Therapeutics Pl...
Streetwise Reports | March 7, 2019 |

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. Ocular Ther...
Streetwise Reports | March 5, 2020 |

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. After the markets closed yesterday afternoon, corneal modeling platform firm Avedro Inc...
Streetwise Reports | August 13, 2019 |

Diagnos increases footprint, and endorsements mount for AI tech that averts illness

Applying Artificial Intelligence (AI) for early detection tests of vascular change in the retina, targeting the diabetes market for vision loss prevention & soon cardiovascular disease. Valuation and Assumptions: Based on due diligence and valuation estimates, Mar...
Fredrick William | June 4, 2020 |